CHARLOTTESVILLE, VA, APRIL 29, 2026 — RIVANNA®, developer of AI-powered clinical decision-support solutions, recently published the findings of a study demonstrating that the novel, automated musculoskeletal imaging system Accuro® XV can produce diagnostic images...
Company accelerates AI-enabled fracture detection development, compressing anticipated FDA 510(k) timeline CHARLOTTESVILLE, VA, APRIL 22, 2026 — RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical...
CHARLOTTESVILLE, VA, DECEMBER 16, 2025 — RIVANNA®, developer of world-first imaging-based medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Accuro® 3S Needle Guide Kit consumables. This...
CHARLOTTESVILLE, VA, OCTOBER 21, 2025 — RIVANNA®, developer of world-first imaging-based medical technologies, has recently been awarded with a Peer-Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award (TTDA) from the Congressionally...
CHARLOTTESVILLE, VA, OCTOBER 2, 2025 — RIVANNA®, developer of world-first imaging-based medical technologies, today announced it has been named a finalist in MedTech Innovator’s (MTI) 2025 Early-Stage Grand Prize competition. The recognition comes as part of the...
CHARLOTTESVILLE, VA, SEPTEMBER 2, 2025 — RIVANNA®, developer of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) Direct to Phase II (R44) grant from the National Cancer Institute (NCI) of the...
CHARLOTTESVILLE, VA – AUGUST 14, 2025 — RIVANNA®, developer of world-first imaging-based medical technologies, was recently awarded grant funding valued at $800,000 from the Virginia Catalyst Program to advance the Accuro® 3S diagnostic ultrasound system. RIVANNA...
CHARLOTTESVILLE, VA – JULY 28, 2025 – RIVANNA®, developer of imaging-based medical technologies, announced that it received $9.92 million in federal funding of a contractual option from the Biomedical Advanced Research and Development Authority (BARDA), part of the...
CHARLOTTESVILLE, VA – JULY 15, 2025 – RIVANNA®, developer of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and...
— One of 65 startups chosen from nearly 1,500 global applicants — — Selected to participate in the world’s leading medtech accelerator — Charlottesville, VA, USA — June 9, 2025 — RIVANNA®, a medical device innovator and manufacturer focused on imaging-based medical...
CHARLOTTESVILLE, VA, DECEMBER 11, 2024 — RIVANNA®, developer of world-first imaging-based medical solutions, has released a report exploring trends in anesthesiology employment across the United States. The findings detail significant regional demand for...
CHARLOTTESVILLE, VA, OCTOBER 8, 2024 — RIVANNA®, developer of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option...
CHARLOTTESVILLE, VA, SEPTEMBER 23, 2024 — RIVANNA®, developer of world-first imaging-based medical solutions, announced the acquisition of a groundbreaking patent for an advanced ultrasound-guided needle insertion system that promises to significantly enhance the...
FOR IMMEDIATE RELEASE CHARLOTTESVILLE, VA, March 28, 2024 — RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and...
CHARLOTTESVILLE, VA, JULY 26, 2023 — RIVANNA®, developer of imaging-based medical solutions, announced that they have received funding totaling $30.5 million over 39 months from early execution of an option by the Biomedical Advanced Research and Development...
Accuro's integration of artificial intelligence with ultrasound (AI-US) provides detailed ultrasound image-analysis pivotal in complex clinical scenarios. CHARLOTTESVILLE, VA, August 16, 2022 — RIVANNA®, developer of world-first, imaging-based medical solutions,...
Medical Technology Leader to Advise Commercialization Strategy for Next-Generation Products CHARLOTTESVILLE, VA, July 7, 2022 — RIVANNA®, developer of world-first, imaging-based medical solutions, has named Nikki Troiano Gainey, a MedTech corporate and...
Experienced Manufacturing Leader Integrates LEAN Principles to Maximize Quality and Productivity CHARLOTTESVILLE, VA, July 13, 2022 — RIVANNA®, developer of world-first, imaging-based medical solutions, has appointed Mikel Lewis, an experienced life science...
CHARLOTTESVILLE, VA, DECEMBER 1, 2021 — RIVANNA®, developer of world-first, imaging-based medical solutions, announced they have entered into a partnership with BOMImed, a recognized manufacturer of anesthesia and critical care related consumables to represent and...
CHARLOTTESVILLE, Virginia — RIVANNA®, developer of world-first, imaging-based medical solutions, today announced the purchase of a 10,000 square-foot facility in Charlottesville, Virginia, with acreage earmarked for new construction. The venture accommodates...
CHARLOTTESVILLE, VA, OCTOBER 26, 2021 — RIVANNA®, developer of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary...
CHARLOTTESVILLE, VA, SEPTEMBER 13, 2021 — RIVANNA®, developer of world-first, imaging-based medical solutions, today announced the results of a recent randomized controlled trial (RCT) showing that Accuro® automated spinal navigation system significantly enhanced...
CHARLOTTESVILLE, VA, September 8, 2021 — RIVANNA®, developer of world-first, imaging-based medical solutions, today announced the results of a prospective, double-blind study demonstrating that the Accuro® Epidural Guidance device with SpineNav3D™ technology...
CHARLOTTESVILLE, VA, August 4, 2021 — RIVANNA®, developer of world-first, imaging-based medical solutions, today announced the first semester of the Teach-Accuro CRNA Educators Project. The new initiative provides the Accuro® spinal navigation system at no cost to...
CHARLOTTESVILLE, VA, July 13, 2021 — RIVANNA®, developer of world-first, imaging-based medical solutions, today announced sales of the Accuro device and related service and equipment increased 263% versus the same period of the prior year following second-quarter...
CHARLOTTESVILLE, VA, JUNE 2, 2021—RIVANNA®, developer of world-first, imaging-based medical solutions, announced the European Patent Office has issued RIVANNA a notice of allowance for European patent application No. 13803513.4 entitled “Ultrasound Imaging of...
CHARLOTTESVILLE, VA, MAY 4, 2021—RIVANNA®, developer of world-first, imaging-based medical solutions, announced they have entered into a partnership with Tri-anim Health Services, a specialty distributor of respiratory, anesthesia, and critical-care supplies, to...
UK's NICE Publishes Medtech Innovation Briefing on Accuro for Guiding Epidural or Spinal Anaesthesia to Reduce Needle Insertions Compared with Palpation Alone in People with Obesity CHARLOTTESVILLE, VA., April 13, 2021—RIVANNA®, developer of world-first,...
RIVANNA Launches Accuro Second Generation With BoneEnhance® Multi-Frequency Image Reconstruction And SpineNav3D™ AI-Based Spine Recognition CHARLOTTESVILLE, VA., March 23, 2021 — RIVANNA®, developer of world-first, imaging-based medical solutions, announces...
Real-time needle guidance for paramedian epidural and spinal anesthesia maximizes image guidance efficiency CHARLOTTESVILLE, VA., November 16, 2020 – RIVANNA® today announced launch of its second-generation Accuro® automated spinal navigation system, combining...
Growing Patent Portfolio Paves the Way for Product Line Expansion CHARLOTTESVILLE, VA., June 26, 2020 — RIVANNA® today announced three new patents for its Accuro® ultrasound-based spinal navigation system, bringing the company's portfolio covering its core...
Palpation alone to determine the appropriate needle trajectory is recognized as a contributing factor in the acquisition of non-diagnostic BMTB specimens [1, 2]. CHARLOTTESVILLE, VA, May 20, 2020 — RIVANNA announced that the company was awarded a $1.5M...
Increasingly Practice Guidelines Recommend Image Guidance for Spinal Needle Placement Procedures CHARLOTTESVILLE, VA., February 19, 2020 — RIVANNA® today announced that sales of its Accuro ultrasound-based spinal navigation system more than doubled in 2019 compared...
Latest Clinical Trial Results Highlight the Benefits of RIVANNA® Accuro® for Spinal Anesthesia in Patients Undergoing Orthopedic Surgery Automated Spinal Navigation Device Reduced Needle Redirects by 48% for Experienced Anesthesia Providers CHARLOTTESVILLE, VA.,...
Rivanna Medical Receives Health Canada Approval for Accuro™ Spinal Navigation System
RIVANNA Announces Multiple Key Patents for Accuro™ and Accuro Locator™
RIVANNA Secures $3.5 Million in Growth Financing
RIVANNA Awarded $1.5M NIH Grant for Rapid Ultrasound-based 3D Bone Fracture Assessment in the Emergency Department
RIVANNA Announces Partnership with UK-based Vertec Scientific
RIVANNA prepares for European Market adoption of Accuro™ with the appointment of a new Vice President of Sales, Europe, the Middle East, and Africa (EMEA)
RIVANNA Launches International Expansion in the Middle East with Easy-to-use, Automated Ultrasound
Accuro™ highlighted in “AORA 2015” scientific presentation by Anand M. Sardesai, MD, Anesthesiologist, Cambridge (UK) University Hospital: “Advances in Ultrasound Machine Technology and Future Trends”
RIVANNA commences manufacturing of its Accuro™ device for launch at annual meeting of the American Society of Anesthesiologists (ASA)
RIVANNA appoints Rebecca D. Minehart, M.D., Assistant Professor of Anesthesia, Massachusetts General Hospital, as a clinical advisor
RIVANNA appoints Brendan Carvalho, M.D., Stanford Univ. Medical Center, as a clinical advisor
RIVANNA has received FDA clearance for Accuro™